Acquired Immunodeficiency Syndrome, HIV Infections, Human Immunodeficiency Virus, Retroviridae Infections, RNA Virus Infections, Sexually Transmitted Diseases, Viral, Virus Diseases, Virus-HIV
Conditions
Keywords
HIV/AIDS, Social Networks, Behavioral Economics, Incentives, PrEP, HIV Self-Testing, Fishermen, Sub Saharan Africa, Men, HIV Prevention
Brief summary
This is a randomized controlled trial to test a combination behavioral and biomedical interventions to improve the HIV prevention and care cascades in a population of mobile men in a high priority setting (fishermen in Kenya). The intervention strategy is to recruit and train highly socially-connected men to distribute HIV self-tests and provide linkage support to men in their close social networks. The study will determine whether this social network-based approach along with small financial incentives in the form of transport vouchers can increase men's self-testing, linkage to and uptake of ART and PrEP after self-testing, virologic suppression at 6 months (for those initiating ART) and PrEP adherence (for those initiating PrEP) at 6 months. The study includes a longitudinal qualitative and mixed methods (quantitative and qualitative assessments) to identify the pathways of intervention action, and understand how the social network-based approach with support for linkage affects testing and ART and PrEP uptake and retention in men.
Detailed description
In Aim 1, following the study pilot, community selection, and preparation the investigators will conduct a census/BMU registry verification in study communities to identify the population of men eligible for the study. The study will screen, recruit and enroll eligible men who give their informed consent to participate, then measure their close social networks identify network-central, highly-connected men (promoters) and randomize their close social network (a cluster) to 1:1 intervention and control groups. Investigators will then conduct a baseline survey to collect socio demographic and baseline sexual behavior data among men in the close social networks. Following this baseline data collection, all promoters will be provided a training. Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration. Promoters in the control group will receive basic HIV education and training about the study, and will be given vouchers that can be exchanged for HIV tests (standard or free HIVST kits) at nearby health facilities. Using follow-up survey data, investigators will test the hypothesis that a higher rate of HIV testing will be observed after 3 months among men in networks that receive the intervention compared to control. In Aim 2, investigators will test whether network-central promoters can enhance linkage to ART and PrEP after HIV testing among men in their close social networks. Promoters in the Aim 1 intervention group will be asked to distribute information and transport vouchers for ART or PrEP when distributing HIV self-tests to men in their close social networks. Investigators will use clinic data to test the primary hypothesis that the intervention will result in higher rates of linkage to ART or PrEP (confirmatory testing and ART referral for positives, and PrEP screening for negatives). Investigators also will test the hypothesis that higher ART and PrEP uptake will be observed within 3 months (+ about one month) in the intervention group. In Aim 3, investigators will measure 6 month VL and 6 month tenofovir levels using viral load testing and a novel point of care PrEP adherence assay (an antibody-based assay permitting measurement of tenofovir levels in urine) in study sites, and test the hypothesis that higher rates of virologic suppression will be observed in HIV-infected men, and PrEP adherence in un-infected men, in the intervention group. Viral load measurements will be conducted by drawing additional venous blood during routine blood draws scheduled for MOH viral load monitoring (as well as additional draws during scheduled appointments for those occurring outside of the annual VL testing standard of care window). PrEP adherence will be measured utilizing the study urine assay at 6 months. HIV treatment adherence will measured through adherence assessment during 3 and 6 routine clinic visits. Across all aims, investigators will assess the pathways of intervention action using qualitative and mixed methods. Investigators will identify the mechanisms of action, and barriers and facilitators of the social network and incentives intervention implementation, using qualitative and mixed methods quantitative and qualitative assessments embedded in Aims 1, 2 and 3. The data collection approach will include in-depth interviews with participants in both groups, key informant interviews with network-central promoters, and focus group discussions with study participants stratified by HIV status and study group. Data will be collected at baseline and three follow-up periods corresponding to the timing of quantitative outcome measurements in Aims 1 through 3.
Interventions
Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
Use of small incentive voucher (\ $5) to encourage linkage to confirmatory testing.
Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support.
Sponsors
Study design
Intervention model description
The study design is a cluster randomized controlled trial where the unit of randomization will be a clusters of men's close social network in study communities.
Eligibility
Inclusion criteria
* Adult (18 years or older) * Male * Working as a fisherman or fishing-related occupation * Willing and able to provide informed consent for participation * Not participating in another research study related to HIV testing, treatment and/or prevention
Exclusion criteria
* Younger than 18 years of age * Female * Included in another intervention study on HIV/AIDS * Inadequate cognitive and/or hearing capacity to complete planned study procedures, at the discretion of the study team
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported HIV Testing | Up to 3 months | Percentage of participants who self-report HIV testing (yes/no) within the past 3 months, measured at 3-month follow-up. |
| Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months | Up to 3 months | The percentage of participants who attended a study-affiliated clinic for HIV treatment or care within 3 months of the intervention baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Linkage to PrEP | Up to 3 months | Percentage of PrEP-eligible HIV-negative participants who initiate PrEP prescription (yes/no), 3-months following confirmatory testing and eligibility screening (combined) |
| Adherence to PrEP (% With Detectable Tenofovir in the Urine) | Up to 6 months | PrEP: Percentage of PrEP-taking HIV-negative participants who are adherent to PrEP (TFV levels of \>= 1500 ng/mL) at 6 months following PrEP initiation. |
| Adherence to ART | Up to 6 months | ART: Percentage of HIV-positive participants who attain viral suppression (HIV RNA \<400 c/mL), 6 months following ART initiation. |
Countries
Kenya
Participant flow
Pre-assignment details
Between June 2021 and March 2022, we enumerated 1,509 fishermen in three beach communities. Among these fishermen, 934 were mapped to social networks and comprised the intent-to-treat sample. Of these, 733 men were reached and completed a baseline survey.
Participants by arm
| Arm | Count |
|---|---|
| Intervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
Provision of multiple self-tests: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
Small monetary incentives: Use of small incentive voucher (\
$5) to encourage linkage to confirmatory testing.
Use of SMS/text reminders to motivate adherence to ART or PrEP: Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support. | 374 |
| Intervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
Provision of multiple self-tests: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
Small monetary incentives: Use of small incentive voucher (\
$5) to encourage linkage to confirmatory testing.
Use of SMS/text reminders to motivate adherence to ART or PrEP: Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support. | 76 |
| Control: Promoter Training and Referral for Testing Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available. | 359 |
| Control: Promoter Training and Referral for Testing Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available. | 79 |
| Total | 888 |
Baseline characteristics
| Characteristic | Control: Promoter Training and Referral for Testing | Total | Intervention: Promoter Training, Multiple HIV Self-test Kit Distribution, and Incentive Distribution |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 7 Participants | 15 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 352 Participants | 718 Participants | 366 Participants |
| Age, Continuous | 37.2 Years | 35.5 Years | 34.5 Years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 359 Participants | 733 Participants | 374 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Kenya | 359 Participants | 733 Participants | 374 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 359 Participants | 733 Participants | 374 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 14 / 374 | 0 / 359 |
| other Total, other adverse events | 1 / 374 | 0 / 359 |
| serious Total, serious adverse events | 14 / 374 | 0 / 359 |
Outcome results
Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months
The percentage of participants who attended a study-affiliated clinic for HIV treatment or care within 3 months of the intervention baseline
Time frame: Up to 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Promoter Training, Multiple Self-test Kits, and Incentives | Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months | 67.3 percentage of participants |
| Short Training and Referral for Testing | Percentage of Participants Who Linked to a Study-affiliated Clinic Within 3 Months | 15.6 percentage of participants |
Self-reported HIV Testing
Percentage of participants who self-report HIV testing (yes/no) within the past 3 months, measured at 3-month follow-up.
Time frame: Up to 3 months
Population: We used cluster adjusted means
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Promoter Training, Multiple Self-test Kits, and Incentives | Self-reported HIV Testing | 65.6 percentage of participants |
| Short Training and Referral for Testing | Self-reported HIV Testing | 31.3 percentage of participants |
Adherence to ART
ART: Percentage of HIV-positive participants who attain viral suppression (HIV RNA \<400 c/mL), 6 months following ART initiation.
Time frame: Up to 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Promoter Training, Multiple Self-test Kits, and Incentives | Adherence to ART | 35.7 percentage of participants |
| Short Training and Referral for Testing | Adherence to ART | 40.2 percentage of participants |
Adherence to PrEP (% With Detectable Tenofovir in the Urine)
PrEP: Percentage of PrEP-taking HIV-negative participants who are adherent to PrEP (TFV levels of \>= 1500 ng/mL) at 6 months following PrEP initiation.
Time frame: Up to 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Promoter Training, Multiple Self-test Kits, and Incentives | Adherence to PrEP (% With Detectable Tenofovir in the Urine) | 18.7 percentage of participants |
| Short Training and Referral for Testing | Adherence to PrEP (% With Detectable Tenofovir in the Urine) | 8.3 percentage of participants |
Linkage to PrEP
Percentage of PrEP-eligible HIV-negative participants who initiate PrEP prescription (yes/no), 3-months following confirmatory testing and eligibility screening (combined)
Time frame: Up to 3 months
Population: We used cluster adjusted means, thus the value does not yield a whole number of participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Promoter Training, Multiple Self-test Kits, and Incentives | Linkage to PrEP | 19.7 percentage |
| Short Training and Referral for Testing | Linkage to PrEP | 19.6 percentage |